Short-term atorvastatin treatment enhances specific antibody production following tetanus toxoid vaccination in healthy volunteers

Vaccine

Volumn 24, Issue 19, 2006, Pages 4035-4040

  Lee, Pui Y ^a   Scumpia, Philip O ^a,b   Byars, Joanne A ^a   Kelly, Kindra M ^a   Zhuang, Haoyang ^a   Shuster, Jonathan S ^a   Theriaque, Douglas W ^a   Segal, Mark S ^a   Reeves, Westley H ^a   Brantly, Mark L ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Atorvastatin; Immune response; Tetanus toxoid; Vaccination

Indexed keywords

ATORVASTATIN; IMMUNOGLOBULIN G1 ANTIBODY; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TETANUS ANTIBODY; TETANUS TOXOID;

ACUTE PHASE RESPONSE; ADULT; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMORAL IMMUNITY; LYMPHOCYTE COUNT; MALE; NORMAL HUMAN; PARAMETER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; TETANUS PROPHYLAXIS; THROMBOCYTE COUNT;

ACUTE-PHASE PROTEINS; ADULT; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; CLOSTRIDIUM TETANI; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; KINETICS; MALE; PYRROLES; TETANUS TOXOID;

EID: 33646125836     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.12.042     Document Type: Article

References (24)

1. Wang K.Y., and Ting C.T. A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol. Jpn Heart J 42 6 (2001) 725-738
2. Simes J., Furberg C.D., Braunwald E., et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling Project. Eur Heart J 23 3 (2002) 207-215
3. Albert M.A., Danielson E., Rifai N., and Ridker P.M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 1 (2001) 64-70
4. Youssef S., Stuve O., Patarroyo J.C., et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420 6911 (2002) 78-84
5. Hakamada-Taguchi R., Uehara Y., Kuribayashi K., et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res 93 10 (2003) 948-956
6. Aktas O., Waiczies S., Smorodchenko A., et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 197 6 (2003) 725-733
7. Goncalves L., Albarran B., Salmen S., et al. The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation. Virology 326 1 (2004) 20-28
8. Schatz D., Ellis T., Ottendorfer E., Jodoin E., Barrett D., and Atkinson M. Aging and the immune response to tetanus toxoid: diminished frequency and level of cellular immune reactivity to antigenic stimulation. Clin Diagn Lab Immunol 5 6 (1998) 894-896
9. Enke B.U., Bokenkamp A., Offner G., Bartmann P., and Brodehl J. Response to diphtheria and tetanus booster vaccination in pediatric renal transplant recipients. Transplantation 64 2 (1997) 237-241
10. Kueppers F. Genetically determined differences in the response of alpha-antitrypsin levels in human serum to typhoid vaccine. Humangenetik 6 3 (1968) 207-214
11. Dolin R., Murphy B.R., and Caplan E.A. Lymphocyte blastogenic responses to influenza virus antigens after influenza infection and vaccination in humans. Infect Immun 19 3 (1978) 867-874
12. Brantly M.L., Wittes J.T., Vogelmeier C.F., Hubbard R.C., Fells G.A., and Crystal R.G. Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes. Chest 100 3 (1991) 703-708
13. Riesen W.F., Engler H., Risch M., Korte W., and Noseda G. Short-term effects of atorvastatin on C-reactive protein. Eur Heart J 23 10 (2002) 794-799
14. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol Sci 23 10 (2002) 482-486
15. Plenge J.K., Hernandez T.L., Weil K.M., et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106 12 (2002) 1447-1452
16. Shimada K., Miyauchi K., and Daida H. Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench. Circulation 109 18 (2004) e213-e214 [author reply e213-214]
17. Ferrante A., Beard L.J., and Feldman R.G. IgG subclass distribution of antibodies to bacterial and viral antigens. Pediatr Infect Dis J 9 8 Suppl. (1990) S16-S24
18. van der Beek M.T., Visser L.G., and de Maat M.P. Yellow fever vaccination as a model to study the response to stimulation of the inflammation system. Vascul Pharmacol 39 3 (2002) 117-121
19. Nielsen H.J., Mortensen T., Holten-Andersen M., Brunner N., Sorensen S., and Rask-Madsen J. Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. Scand J Gastroenterol 36 3 (2001) 265-269
20. Beckman J.A., Liao J.K., Hurley S., et al. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res 95 2 (2004) 217-223
21. Montero M.T., Hernandez O., Suarez Y., et al. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis 153 2 (2000) 303-313
22. Montero M.T., Matilla J., Gomez-Mampaso E., and Lasuncion M.A. Geranylgeraniol regulates negatively caspase-1 autoprocessing: implication in the Th1 response against Mycobacterium tuberculosis. J Immunol 173 8 (2004) 4936-4944
23. Yilmaz A., Reiss C., Tantawi O., et al. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 172 1 (2004) 85-93
24. Veldman C., Stauber A., Wassmuth R., Uter W., Schuler G., and Hertl M. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. J Immunol 170 1 (2003) 635-642